Mangoceuticals (MGRX) Institutional Ownership $2.81 -1.94 (-40.84%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$2.81 0.00 (0.00%) As of 03/25/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Mangoceuticals (NASDAQ:MGRX)CurrentInstitutional OwnershipPercentage56.72%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$46.38MNumber ofInstitutional Sellers(last 12 months)2TotalInstitutional Outflows(last 12 months)$2.32M Get MGRX Insider Trade Alerts Want to know when executives and insiders are buying or selling Mangoceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data MGRX Institutional Buying and Selling by Quarter Remove Ads Mangoceuticals Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/12/2025 Geode Capital Management LLC12,003$29K0.0%-90.9%0.482% 2/4/2025 Ackerman Capital Advisors LLC34,500$83K0.0%-96.0%1.386% 10/24/2024 Ackerman Capital Advisors LLC873,356$206K0.1%N/A3.519% 8/8/2023 Colonial River Wealth Management LLC36,100$66K0.0%N/A0.216% 7/28/2023 Independent Advisor Alliance26,000$48K0.0%N/A0.162% (Data available from 1/1/2016 forward)Remove Ads MGRX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of MGRX shares? During the previous two years, the following institutional investors and hedge funds held shares of Mangoceuticals shares: Ackerman Capital Advisors LLC ($83K), Colonial River Wealth Management LLC ($66K), and Independent Advisor Alliance ($48K), Geode Capital Management LLC ($29K).Learn more on MGRX's institutional investors. What percentage of Mangoceuticals stock is owned by institutional investors? 56.72% of Mangoceuticals stock is owned by institutional investors. Learn more on MGRX's institutional investor holdings. Which institutional investors have been buying Mangoceuticals stock? The following institutional investors have purchased Mangoceuticals stock in the last 24 months: Ackerman Capital Advisors LLC ($873.36K), Colonial River Wealth Management LLC ($36.10K), and Independent Advisor Alliance ($26K). How much institutional buying is happening at Mangoceuticals? Institutional investors have bought a total of 935,456 shares in the last 24 months. This purchase volume represents approximately $71.94M in transactions. Which Mangoceuticals major shareholders have been selling company stock? The following institutional investors have sold Mangoceuticals stock in the last 24 months: Ackerman Capital Advisors LLC ($838.86K), and Geode Capital Management LLC ($119.32K). How much institutional selling is happening at Mangoceuticals? Institutional investors have sold a total of 958,180 shares in the last 24 months. This volume of shares sold represents approximately $2.32M in transactions. Related Companies ENZ Major Shareholders CCM Major Shareholders OPGN Major Shareholders BRTX Major Shareholders KDLY Major Shareholders SSY Major Shareholders BGLC Major Shareholders ATIP Major Shareholders VSEE Major Shareholders NIVF Major Shareholders This page (NASDAQ:MGRX) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mangoceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mangoceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
